CURRENT
ISSUE
1707

The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved only for adults ≥60 years old.1 Two other RSV vaccines have received FDA approval: Abrysvo, a recombinant vaccine that is licensed for use in adults ≥60 years old and in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants,1 and mResvia, an mRNA vaccine recently licensed for use in...  Continue reading

Coming Soon
Drugs for Epilepsy
Qlosi – Pilocarpine 0.4% Ophthalmic Solution for Presbyopia
Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis